What this means
Researchers plan to test whether three weeks of virtual reality brain training plus a daily supplement improves thinking skills. This trial is still recruiting, so no results are available yet.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 35–75
- Where
- 1 site
The science
- Registered title
- Epigenetic Enhancement of Cognitive Training in Aging Mood and Schizophrenia Spectrum Disorder Populations
- Trial ID
- NCT07404085 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Bipolar Disorder (BD), Depression - Major Depressive Disorder, Cognitive Impairment, Schizophrenia Disorders
- What is tested
- Virtual Reality-based cognitive remediation therapy (VR-CRT), Virtual Reality-based control treatment (VR-CT), HDACi butyrate, Placebo
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
- Ages
- 35 Years to 75 Years
- Dates
- First posted Feb 11, 2026 · updated Oct 7, 2026
Registry summary
The aim of this clinical trial is to investigate the effects of a three-week virtual reality-based cognitive remediation training (VR-CRT) programme in combination with daily intake of a histone deacetylase inhibitor (HDACi) sodium butyrate on cognition in symptomatically stable patients with mood (depression or bipolar disorder; MD) or schizophrenia spectrum disorders.
The investigators hypothesize that the VR-based cognitive remediation training (VR-CRT) combined with HDACi butyrate vs. a VR-based control treatment combined with placebo will improve global cognition (primary outcome measure) over three weeks.
Secondly, the investigators hypothesize that VR-CRT with placebo will improve cognition relative to the VR control treatment with placebo, although to a lesser extent than VR-CRT with HDACi butyrate.
Thirdly, the investigators hypothesize that the HDACi butyrate with VR control treatment will not produce cognitive improvements relative to placebo with VR control treatment.
Finally, the investigators hypothesize that the combined treatment (VR-CRT + HDACi butyrate) will enhance neuroplasticity (exploratory outcome) vs. VR control with placebo, as indicated by increase in hippocampal volume and/or memory-related activity shown with structural and functional MRI.
Sites (1)
- Neurocognition and Emotion Across Disorders (NEAD Brain Centre, Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Frederiksberg Hospital, Frederiksberg, Capital Region of Denmark, Denmark